Drug Alert: Amoxicillin Sodium 1g, 250mg and 500mg Powder for Solution for Injection – NOT FOR neonates and infants below one year old

by Kazeem Olalekan MRPharmS The Medicines and Healthcare products Regulatory Agency has just issued a Class 4 Drug Safety Alert for Wockhardt UK Ltd – Amoxicillin Sodium 1g, 250mg and 500mg Powder for Solution for Injection. Alert details Drug alert number EL (14)A/09 in connection with the above products was issued on 9 July 2014. […]

What’s New? The BNF and BNFc updates

by Kazeem Olalekan A BNF and BNFc app convert like myself knows to press the ‘Update Now’ button whenever I am prompted to do so. It is the best way to be up-to-date in clinical decision making. What I thought I would do today is highlight some key updates in the BNF and BNFc in […]

Febuxostat (Adenuric) and hypersensitivity reaction

by Kazeem Olalekan Attention has just been drawn to the Drug Safety Update on Febuxostat (Adenuric) via the PJOnline website. In summary, there have been rare but serious reports of hypersensitivity reactions, including Stevens-Johnson syndrome and acute anaphylactic shock, with febuxostat (Adenuric). Febuxostat must be stopped immediately if hypersensitivity occurs, and must not be re-started […]

Take note: PPIs and emerging issues

by Kazeem Olalekan MRPharmS In August 2009 we reported a potential interaction between Proton pump inhibitors (PPI) and Clopidogrel. Subsequent to that report, Lancet concluded that PPI does not interfere with the clinical benefits of clopidogrel. The case frustrated me because in one week I was asking my GPs to review prescribing and in the […]

Drug Safety Alert – Dronedarone

Dronedarone (Multaq▼) is an antiarrhythmic agent indicated in adult, clinically stable patients with history of, or current, non-permanent atrial fibrillation (AF) to prevent recurrence of AF or to lower ventricular rate. Dronedarone is available as a 400 mg film-coated tablet and the recommended dose is 400 mg twice daily. Dronederone was only approved by NICE […]